Trial Details

85728 (B)
The study drug will involve a new compound being developed for the treatment of Multiple Sclerosis (MS). MS is the leading cause of neurological disability in young adults and is the most common disorder of the central nervous system.

You may be eligible to apply for this study if:

Women who might wish to participate must have been surgically sterilised for at least 6 months, or have been postmenopausal for at least 1 year.

Men who might wish to participate must be willing to use a double barrier method of contraception from the start of the study and for three months after completion of the study

You must be a non smoker and not have used any nictine containing products in the last 3 months

Participants must weigh more than 70kg and have a body mass index (BMI) of 18-30kg/m²

You will not be eligible to apply for this study if:

You have received a vaccination in the last 2 months

You have been a blood donor in the last 2 months

You have any current illness

You have any acute or chronic infectious disease in your medical history

You a history of fainting

You have any heart failure or left ventricular dysfunction in your family

You have any allergies to medication

You have history of respiratory disease

You have a history of any liver or kidney disease

You have tested positive for hepatitis B, C or HIV

You have a history of alcohol or drug abuse

Screening Dates:

Please call 01895 614888 for latest screening schedule.

Dates of In-house stay:

Tuesday 26th August - Monday 1st September 2008 and Tuesday 16th September - Monday 22nd September

Outpatient visit dates:

Wed 3rd Sept , Sat 6th Sept, Thur 11th Sept, Wed 24th Sept, Sat 27th Spet

Follow up visit:

Thursday 2nd October

« Back to Trials

The PAREXEL Clinical Pharmacology Research Unit
Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ
VOLUNTEER FREEPHONE - 0800 389 8930 | Email: drugtrial@parexel.com